Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Zyprex Phase III results show 3-point advantage in schizophrenia symptom score v. haloperidol .

Executive Summary

LILLY ZYPREX SHOWS THREE-POINT ADVANTAGE IN SCHIZOPHRENIA SYMPTOM SCORE over haloperidol treatment based on six-week data in a Phase III study presented Dec. 15 at the American College of Neuropsychopharmacology meeting in San Juan, P.R. Patients receiving Lilly's antipsychotic Zyprex (olanzapine) showed an average decrease of 10.9 points on the Brief Psychiatric Rating Scale compared to an average decrease of 7.9 points for haloperidol-treated patients, Lilly said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel